Clinical Study of Anlotinib as Third-Line or Above Therapy in Patients With Advanced or Metastatic Gastric Cancer: A Multicenter Retrospective Study

BACKGROUND: The present study was conducted to evaluate the efficacy and safety of anlotinib as third-line or above therapy for patients with advanced or metastatic gastric cancer. METHODS: Patients with advanced or metastatic gastric cancer who have failed from second-line treatment and treated wit...

Descripción completa

Detalles Bibliográficos
Autores principales: Nie, Caiyun, He, Yunduan, Lv, Huifang, Gao, Ming, Gao, Xiaohui, Chen, Beibei, Xu, Weifeng, Wang, Jianzheng, Liu, Yingjun, Zhao, Jing, Chen, Xiaobing
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9289113/
https://www.ncbi.nlm.nih.gov/pubmed/35860585
http://dx.doi.org/10.3389/fonc.2022.885350

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9289113/
https://www.ncbi.nlm.nih.gov/pubmed/35860585
http://dx.doi.org/10.3389/fonc.2022.885350

Ejemplares similares